Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Lacrimal Apparatus Diseases 1Lacerations 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endophthalmitis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 30Docetaxel 10Cetuximab 10Trastuzumab 9Paclitaxel 7Nivolumab 6Magnetic Resonance Spectroscopy 6palbociclib 5cemiplimab 5Gemcitabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5Biopsy 5durvalumab 4atezolizumab 4Surveys and Questionnaires 4Radiotherapy 4Fulvestrant 4Fluorodeoxyglucose F18 4Drug Therapy 4Cisplatin 4selpercatinib 3poly ICLC 3pazopanib 3fludarabine 3avelumab 3Taxes 3Sunitinib 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Fluorometholone × Head & Neck × Clear all
NCT00824811 2012-08-02

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

M.D. Anderson Cancer Center

Phase 2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Lacrimal Apparatus Diseases, Lung Neoplasms, Endophthalmitis, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Lacerations, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡